provided to the patient, including the name of the biological product and the manufacturer. The communication must be conveyed by making an entry that is electronically accessible to the prescriber through: (i) an interoperable electronic medical records system; (ii) an electronic prescribing technology; (iii) a pharmacy benefit management system; or (iv) a pharmacy record. Entry into an electronic records system as described in this section is presumed to provide notice to the prescriber. Otherwise, the pharmacist shall communicate the biological product dispensed to the prescriber using facsimile, telephone, electronic transmission, or other prevailing means, provided that communication is not required when: (a) there is no federal Food and Drug Administration approved interchangeable biological product for the product prescribed; or (b) a refill prescription is not changed from the product dispensed on the prior filling of the prescription; or (c) a biological product is dispensed for inpatient hospital services or is a hospital-administered biological product for outpatients. (8) The board shall maintain a link on its website to the current list of all biological products that the federal Food and Drug Administration has determined to be interchangeable biological products.” SECTION 6. This act takes effect upon approval by the Governor. XX
provided to the patient, including the name of the biological product and the manufacturer. The communication must be conveyed by making an entry that is electronically accessible to the prescriber through: (i) an interoperable electronic medical records system; (ii) an electronic prescribing technology; (iii) a pharmacy benefit management system; or (iv) a pharmacy record. Entry into an electronic records system as described in this section is presumed to provide notice to the prescriber. Otherwise, the pharmacist shall communicate the biological product dispensed to the prescriber using facsimile, telephone, electronic transmission, or other prevailing means, provided that communication is not required when: (a) there is no federal Food and Drug Administration approved interchangeable biological product for the product prescribed; or (b) a refill prescription is not changed from the product dispensed on the prior filling of the prescription; or (c) a biological product is dispensed for inpatient hospital services or is a hospital-administered biological product for outpatients. (8) The board shall maintain a link on its website to the current list of all biological products that the federal Food and Drug Administration has determined to be interchangeable biological products.” SECTION 6. This act takes effect upon approval by the Governor. XX